See more : Toin Corporation (7923.T) Income Statement Analysis – Financial Results
Complete financial analysis of Celldex Therapeutics, Inc. (CLDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Celldex Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Northern Lights Acquisition Corp. (NLITU) Income Statement Analysis – Financial Results
- Integrated Business Systems & Services, Inc. (IBSS) Income Statement Analysis – Financial Results
- Visium Technologies, Inc. (VISM) Income Statement Analysis – Financial Results
- Anji Foodstuff Co., Ltd (603696.SS) Income Statement Analysis – Financial Results
- LEM Holding SA (0QKB.L) Income Statement Analysis – Financial Results
Celldex Therapeutics, Inc. (CLDX)
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.88M | 2.36M | 4.65M | 7.42M | 3.57M | 9.54M | 12.74M | 6.79M | 5.48M | 3.59M | 4.11M | 11.20M | 9.27M | 46.79M | 15.18M | 7.46M | 5.10M | 4.93M | 3.09M | 6.86M | 4.63M | 6.70M | 3.35M | 763.20K | 1.48M | 2.20M | 1.20M | 1.10M | 4.00M | 7.00M | 9.00M | 6.60M | 10.20M | 10.90M | 7.80M | 4.60M | 2.20M | 100.00K |
| Cost of Revenue | 3.01M | 1.40M | 3.07M | 42.53M | 42.67M | 66.45M | 96.17M | 102.03M | 4.01M | 101.88M | 2.33M | 10.78M | 9.12M | 12.08M | 8.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 41.00K | 36.80K | -689.30K | -712.80K | -400.00K | -300.00K | -100.00K | 1.20M | 1.20M | 1.50M | 600.00K | 1.10M | 800.00K | 800.00K | 300.00K | -100.00K | 0.00 |
| Gross Profit | 3.88M | 957.00K | 1.58M | -35.12M | -39.10M | -56.91M | -83.43M | -95.24M | 1.47M | -98.30M | 1.78M | 427.00K | 146.00K | 34.72M | 6.78M | 7.46M | 5.10M | 4.93M | 3.09M | 6.86M | 4.63M | 6.66M | 3.31M | 1.45M | 2.20M | 2.60M | 1.50M | 1.20M | 2.80M | 5.80M | 7.50M | 6.00M | 9.10M | 10.10M | 7.00M | 4.30M | 2.30M | 100.00K |
| Gross Profit Ratio | 56.30% | 40.60% | 34.04% | -473.39% | -1,094.29% | -596.68% | -654.70% | -1,403.48% | 26.81% | -2,741.08% | 43.23% | 3.81% | 1.58% | 74.19% | 44.68% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 99.39% | 98.90% | 190.32% | 148.05% | 118.18% | 125.00% | 109.09% | 70.00% | 82.86% | 83.33% | 90.91% | 89.22% | 92.66% | 89.74% | 93.48% | 104.55% | 100.00% |
| Research & Development | 118.01M | 82.26M | 53.31M | 42.53M | 42.67M | 66.45M | 96.17M | 102.73M | 100.17M | 104.38M | 67.40M | 47.40M | 32.44M | 27.65M | 26.17M | 26.35M | 18.50M | 18.07M | 14.06M | 13.87M | 10.02M | 14.71M | 21.58M | 10.77M | 7.87M | 5.70M | 5.30M | 6.00M | 8.00M | 8.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 30.91M | 27.20M | 20.49M | 14.46M | 15.43M | 19.27M | 25.00M | 35.98M | 33.84M | 20.62M | 14.81M | 10.02M | 9.24M | 10.43M | 17.12M | 14.75B | 8.50B | 0.00 | 6.89B | 0.00 | 0.00 | 0.00 | 4.91M | 4.81M | 4.28M | 3.80M | 3.50M | 6.50M | 5.90M | 5.80M | 16.00M | 0.00 | 12.90M | 11.50M | 8.30M | 6.10M | 3.70M | 1.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -14.73B | -8.49B | 0.00 | -6.89B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.91M | 27.20M | 20.49M | 14.46M | 15.43M | 19.27M | 25.00M | 35.98M | 33.84M | 20.62M | 14.81M | 10.02M | 9.24M | 10.43M | 17.12M | 14.75M | 8.50M | 8.24M | 6.89M | 5.57M | 5.35M | 5.59M | 4.91M | 4.81M | 4.28M | 3.80M | 3.50M | 6.50M | 5.90M | 5.80M | 16.00M | 10.10M | 12.90M | 11.50M | 8.30M | 6.10M | 3.70M | 1.90M |
| Other Expenses | 12.50M | 90.34M | 55.38M | 54.02M | 42.71M | 224.00K | 896.00K | 997.00K | 1.01M | 1.01M | 1.01M | 1.09M | 1.91M | 3.14M | 345.00K | 361.01K | 960.21K | 995.11K | 995.11K | 995.10K | 995.10K | 795.10K | 1.38M | 1.31M | 1.99M | 1.00M | 400.00K | 500.00K | 700.00K | 800.00K | 900.00K | 600.00K | 600.00K | 500.00K | 300.00K | 200.00K | 200.00K | 100.00K |
| Operating Expenses | 161.43M | 109.45M | 73.80M | 56.99M | 58.10M | 85.94M | 122.07M | 139.70M | 135.02M | 126.02M | 83.22M | 58.50M | 43.60M | 41.17M | 43.63M | 41.46M | 27.96M | 27.30M | 21.95M | 20.44M | 16.37M | 21.10M | 27.87M | 16.89M | 14.14M | 10.50M | 9.20M | 13.00M | 14.60M | 15.30M | 16.90M | 10.70M | 13.50M | 12.00M | 8.60M | 6.30M | 3.90M | 2.00M |
| Cost & Expenses | 161.43M | 109.45M | 73.80M | 56.99M | 58.10M | 85.94M | 122.07M | 139.70M | 135.02M | 126.02M | 85.55M | 69.28M | 52.71M | 53.25M | 52.03M | 41.46M | 27.96M | 27.30M | 21.95M | 20.44M | 16.37M | 21.14M | 27.91M | 16.20M | 13.43M | 10.10M | 8.90M | 12.90M | 15.80M | 16.50M | 18.40M | 11.30M | 14.60M | 12.80M | 9.40M | 6.60M | 3.80M | 2.00M |
| Interest Income | 13.11M | 0.00 | 505.00K | 2.41M | 4.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 530.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 151.09M | 15.97M | 0.00 | 0.00 | 0.00 | 927.00K | 1.58M | 1.80M | 1.34M | 452.00K | 156.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.01M | 1.40M | 3.07M | 2.00M | 4.86M | 3.80M | 5.31M | 4.09M | 1.01M | 1.01M | 2.95M | 1.09M | 1.91M | 3.14M | 3.53M | 2.54M | 2.69M | 2.10M | 2.13M | 1.72M | 1.53M | 1.62M | 2.26M | 1.31M | 1.99M | 1.00M | 400.00K | 500.00K | 700.00K | 800.00K | 900.00K | 600.00K | 600.00K | 500.00K | 300.00K | 200.00K | 200.00K | 100.00K |
| EBITDA | -139.03M | -104.20M | -66.08M | -45.64M | -49.67M | -72.60M | -104.02M | -124.44M | -125.53M | -116.53M | -77.68M | -54.41M | -38.84M | 4.67M | -33.07M | -44.96M | -19.07M | -18.16M | -16.50M | -11.82M | -10.21M | -12.81M | -22.30M | -14.13M | -9.96M | -6.95M | -7.31M | -11.30M | -11.10M | -8.70M | -8.50M | -4.10M | -5.90M | -3.80M | -1.40M | -1.30M | -1.80M | -1.40M |
| EBITDA Ratio | -2,019.96% | -4,321.89% | -1,452.55% | -514.92% | -1,628.10% | -6.66% | -753.60% | -2,008.62% | -2,388.18% | -3,385.86% | -1,909.44% | -508.72% | -453.12% | -7.08% | -219.49% | -240.92% | -416.70% | -453.96% | -566.77% | -178.53% | -225.49% | -200.04% | -720.66% | -995.26% | -713.91% | 1,677.27% | -150.00% | -1,118.18% | -367.50% | -94.29% | -107.78% | -74.24% | -46.08% | -20.18% | -25.64% | -56.52% | -104.55% | -1,900.00% |
| Operating Income | -154.54M | -115.23M | -71.24M | -63.35M | -55.03M | -156.44M | -121.53M | -132.92M | -129.54M | -122.43M | -81.44M | -58.08M | -43.40M | -6.46M | -36.85M | -48.76M | -22.85M | -22.37M | -18.87M | -13.58M | -11.73M | -14.43M | -24.56M | -15.44M | -11.94M | -7.90M | -7.70M | -11.80M | -11.80M | -9.50M | -9.40M | -4.70M | -4.40M | -1.90M | -1.60M | -2.00M | -1.60M | -1.90M |
| Operating Income Ratio | -2,245.27% | -4,889.01% | -1,531.78% | -854.06% | -1,540.19% | -1,640.13% | -953.68% | -1,958.68% | -2,363.89% | -3,414.11% | -1,981.08% | -518.45% | -468.42% | -13.79% | -242.75% | -653.96% | -447.88% | -453.60% | -610.85% | -198.03% | -253.28% | -215.25% | -734.07% | -2,023.17% | -805.14% | -359.09% | -641.67% | -1,072.73% | -295.00% | -135.71% | -104.44% | -71.21% | -43.14% | -17.43% | -20.51% | -43.48% | -72.73% | -1,900.00% |
| Total Other Income/Expenses | 13.11M | 2.91M | 505.00K | 2.41M | 4.15M | 4.49M | 4.21M | 4.39M | 2.34M | 4.35M | -108.00K | -1.05M | -1.35M | 3.92M | -4.20M | 1.26M | -6.25M | 2.11M | 768.45K | 378.60K | 239.80K | 602.70K | 1.81M | -6.53M | 635.20K | 49.60K | -5.50M | 1.00M | 3.60M | -2.10M | 1.20M | 800.00K | 3.00M | 3.30M | 1.00M | 800.00K | 1.30M | 100.00K |
| Income Before Tax | -141.43M | -112.33M | -70.74M | -60.95M | -50.88M | -151.95M | -117.31M | -128.53M | -127.20M | -118.08M | -81.55M | -59.12M | -44.80M | -2.53M | -37.05M | -62.26M | -21.76M | -20.25M | -18.10M | -13.20M | -11.49M | -13.83M | -22.75M | -21.98M | -11.31M | -7.90M | -13.20M | -10.80M | -8.20M | -11.60M | -8.20M | -3.90M | -3.50M | -1.10M | -900.00K | -1.20M | -700.00K | -1.80M |
| Income Before Tax Ratio | -2,054.76% | -4,765.59% | -1,520.92% | -821.61% | -1,423.96% | -1,593.09% | -920.61% | -1,894.05% | -2,321.11% | -3,292.81% | -1,983.70% | -527.79% | -483.53% | -5.41% | -244.10% | -835.04% | -426.40% | -410.74% | -585.96% | -192.51% | -248.10% | -206.26% | -680.03% | -2,879.32% | -762.33% | -359.09% | -1,100.00% | -981.82% | -205.00% | -165.71% | -91.11% | -59.09% | -34.31% | -10.09% | -11.54% | -26.09% | -31.82% | -1,800.00% |
| Income Tax Expense | 0.00 | 10.46M | -227.00K | -1.17M | -506.00K | -765.00K | -24.28M | -8.77M | -2.34M | -4.35M | -819.00K | -530.00K | -446.00K | -5.31M | -529.00K | 27.00M | -120.00K | 120.00K | -1.54M | -757.20K | 695.70K | -1.21M | -3.62M | 13.07M | -1.27M | 87.70M | 10.90M | -2.00M | -7.10M | 4.20M | -2.80M | -1.90M | -1.90M | -1.70M | -1.20M | -1.60M | -1.70M | -300.00K |
| Net Income | -141.43M | -122.78M | -70.51M | -59.78M | -50.37M | -151.18M | -93.03M | -128.53M | -127.20M | -118.08M | -81.55M | -59.12M | -44.80M | -2.53M | -36.53M | -47.50M | -21.64M | -20.37M | -18.10M | -13.20M | -12.67M | -13.83M | -22.75M | -21.98M | -11.31M | -51.80M | -13.10M | -10.80M | -8.30M | -11.60M | -7.80M | -3.60M | -3.40M | -1.00M | -1.10M | -1.20M | -800.00K | -1.70M |
| Net Income Ratio | -2,054.76% | -5,209.29% | -1,516.04% | -805.88% | -1,409.80% | -1,585.07% | -730.06% | -1,894.05% | -2,321.11% | -3,292.81% | -1,983.70% | -527.79% | -483.53% | -5.41% | -240.61% | -637.12% | -424.05% | -413.17% | -585.96% | -192.51% | -273.47% | -206.26% | -680.03% | -2,879.32% | -762.33% | -2,354.55% | -1,091.67% | -981.82% | -207.50% | -165.71% | -86.67% | -54.55% | -33.33% | -9.17% | -14.10% | -26.09% | -36.36% | -1,700.00% |
| EPS | -2.92 | -2.62 | -1.64 | -2.02 | -3.47 | -14.48 | -10.86 | -18.99 | -19.66 | -19.81 | -15.33 | -15.37 | -17.01 | -1.19 | -27.64 | -50.12 | -468.75 | -49.41 | -43.93 | -32.57 | -36.48 | -41.17 | -70.63 | -75.43 | -46.18 | -281.04 | -89.06 | -89.61 | -85.46 | -122.55 | -82.48 | -48.26 | -57.95 | -18.89 | -23.80 | -26.22 | -17.49 | -37.21 |
| EPS Diluted | -2.92 | -2.62 | -1.64 | -2.02 | -3.47 | -14.48 | -10.86 | -18.99 | -19.66 | -19.81 | -15.33 | -15.37 | -17.01 | -1.19 | -27.64 | -50.12 | -468.75 | -49.41 | -43.93 | -32.57 | -36.48 | -41.17 | -70.63 | -75.43 | -46.18 | -281.04 | -89.06 | -89.61 | -85.46 | -122.55 | -82.48 | -48.26 | -57.95 | -18.89 | -23.80 | -26.22 | -17.49 | -37.21 |
| Weighted Avg Shares Out | 48.45M | 46.89M | 42.87M | 29.64M | 14.51M | 10.44M | 8.57M | 6.77M | 6.47M | 5.96M | 5.32M | 3.85M | 2.63M | 2.12M | 1.32M | 947.80K | 46.16K | 412.31K | 411.91K | 405.36K | 347.29K | 335.90K | 322.12K | 291.32K | 244.87K | 184.32K | 147.10K | 120.52K | 97.12K | 94.66K | 94.57K | 74.59K | 58.67K | 52.93K | 46.22K | 45.77K | 45.75K | 45.69K |
| Weighted Avg Shares Out (Dil) | 48.45M | 46.89M | 42.87M | 29.64M | 14.51M | 10.44M | 8.57M | 6.77M | 6.47M | 5.96M | 5.32M | 3.85M | 2.63M | 2.12M | 1.32M | 947.80K | 46.16K | 412.31K | 411.91K | 405.36K | 347.29K | 335.90K | 322.12K | 291.32K | 244.87K | 184.32K | 147.10K | 120.52K | 97.12K | 94.66K | 94.57K | 74.59K | 58.67K | 52.93K | 46.22K | 45.77K | 45.75K | 45.69K |
FMR LLC's Top 5 Buys in September
FMR LLC, the Boston-based asset management company commonly known as Fidelity, disclosed this month that its top-five trades during September included new buys in Toast Inc. ( TOST , Financial), Graphite Bio Inc. ( GRPH , Financial) and Absci Corp....
Celldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clinical Benefit in Phase 1b Study in Chronic Inducible Urticaria at EADV 2021
- Rapid and sustained improvement in urticaria control after single dose of CDX-0159 - - Greatly improved patient quality of life and reduced disease impact - - Data further support 95% complete response rate to provocation testing -
Celldex to Present at the 2021 Cantor Virtual Global Healthcare Conference
HAMPTON, N.J., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 1:20 p.m. ET.
Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers
Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers
Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Academy of Dermatology and Venereology (EADV) 30th Congress
HAMPTON, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing symptom control and quality of life measurements from the Phase 1b study of CDX-0159 in patients with antihistamine refractory cold contact urticaria...
Celldex (CLDX) Initiates Subcutaneous Skin Disorder Drug Study
Celldex (CLDX) is developing subcutaneous as well as intravenous formulations of its antibody candidate, CDX-0159 as a potential treatment of several skin disorders.
Celldex Announces Initiation of CDX-0159 Subcutaneous Formulation Study
HAMPTON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first cohort has been dosed in the Phase 1 study of the subcutaneous formulation of CDX-0159 in healthy volunteers. CDX-0159 is a humanized monoclonal...
Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of 15.00% and 207.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
How Good Were Celldex Therapeutics' Latest Clinical Results?
The short answer: They were impressive.
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
HAMPTON, N.J., July 16, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 6,845,238 shares of its common stock, which includes the exercise in...
Source: https://incomestatements.info
Category: Stock Reports